BRAF and melanoma: Additionally, the SECOMBIT trial demonstrated that sequential immunotherapy (nivolumab plus ipilimumab) and targeted therapy (encorafenib plus binimetinib) provide clinically significant survival benefits in patients with BRAF-mutant melanoma [97].